What are your top takeaways in Hematologic Malignancies from ASCO 2026?

1. Phase III SENTRY study of ruxolitinib +/- selinexor in myelofibrosis - The combination arm met the spleen response endpoint, had similar rates of symptom improvement compared to ruxolitinib, and, with short follow-up, there appears to be a signal towards survival benefit. Longer-term follow-up will...

1. MajesTEC-9 study: Started teclistamab in a real-world post-lenalidomide and CD38 population.
2. SUCCESSOR-2 study: 1st randomized data on a celmod, which represents a now active oral drug class.
3. Kelonia CAR-T: Exciting early data on an in vivo CAR T, which could represent a paradigm shift in the futur...

1. It is not really hematology, but it was so compelling that I will list it- the presentation reporting that the RAS-targeting drug daraxonrasib doubled overall survival in pancreatic cancer. Clearly important for RAS-driven tumors, but the chemistry behind it will benefit efforts to target previou...

1. MajesTEC-9 trial. In my opinion, this is a very relevant study in today’s treatment era (where everybody receives upfront anti-CD38 mAb therapy). There was substantial PFS benefit, and the study included rapid de-escalation of teclistamab dosing frequency. I think single-agent teclistamab will be an...

As always, lots of compelling data were presented at ASCO highlighting the advancements we continue to see in the treatment of plasma cell disorders. My top takeaways include:

1. Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis: for de...

frontMIND – Study evaluating the benefit of R2-tafa+ CHOP compared to R-CHOP in patients with newly diagnosed DLBCL. The study demonstrated a PFS benefit of the experimental arm (R2-tafa-CHOP) vs. R-CHOP. There was no OS benefit. The study indicated increased toxicity with the experimental arm, but ...

• I think some of the most impressive were the data on elranatamab in smoldering MM and the ERASMM study from Europe.
• Linvoseltamab data in AL amyloidosis in the relapsed setting.
• And the KLN-1010 in vivo CART data for relapsed myeloma.